Download PDF
Z Gastroenterol 2005; 43(7): 689-690
DOI: 10.1055/s-2005-858274
Kommentiertes Referat

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Adalimumab bei Patienten mit therapierefraktärem M. Crohn - die nächste Generation der anti-TNF-α-Therapie?

Adalimumab in Infliximab Refractory Crohn's Disease - the next Generation of anti-TNF-α-therapy?J. Heidemann1 , T. Kucharzik1
  • 1Medizinische Klinik und Poliklinik B, Universitätsklinikum Münster
Further Information

Publication History

Publication Date:
07 July 2005 (online)

Also available at
    Permissions and Reprints

Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 75 - 79

Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 333 - 338

Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 1984 - 1989

Prof. Dr. med. T. Kucharzik

Medizinische Klinik und Poliklinik B, Universitätsklinikum Münster

Albert-Schweitzer-Str. 33

D-48129 Münster

Phone: 02 51/8 34 75 74

Fax: 02 51/8 34 75 76

Email: kucharz@uni-muenster.de

      >